Agilis Biotherapeutics Names Former H. Lundbeck A/S Executive, Christopher J. Silber, MD, As Chief Medical Officer

CAMBRIDGE, Mass.--(BUSINESS WIRE)--Agilis Biotherapeutics, LLC (Agilis), a biotechnology company advancing innovative gene therapy products for the treatment of rare genetic diseases that affect the central nervous system (CNS), announced today that the Company has appointed Christopher J Silber, MD, as its Chief Medical Officer. Dr. Silber has more than 25 years of clinical development leadership experience in the pharmaceutical industry including orphan drug development, with extensive therapeutic experience in neuroscience. Prior to joining Agilis, he spent seven years at H. Lundbeck A/S, a company specializing in brain disease, in senior management positions, including most recently Vice President US Clinical Development Center.

Back to news